The in vivo administration of monoclonal antibodies targeted to CD4 and CD52 has recently been proposed for the treatment of patients with PTCL.99 However, in our experience this should be regarded with caution when referring to PTCL/NOS. Here, CD52 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.